News

The double-blind, randomized, placebo-controlled LUME-COLON 1 trial will evaluate the efficacy and safety of nintedanib plus best supportive care (BSC), versus placebo plus BSC, after previous treatment with

While the current focus of the Company’s PolyStart technology is on TapImmune’s cancer program (e.g., Her2/neu and folate receptor alpha antigens), the Company none-the-less strongly reaffirms that this

Apart from the EMA orphan designation status, the company has also received fast track designation by the US Food and Drug Administration (FDA) for Epidiolex to treat Dravet

This expanded program will combine the strength of the iBioLaunch platform with Novici’s patented GRAMMR technology for rapid evolution of gene sequences to significantly increase expression yield of

This new agreement follows the December 2012 collaboration between the two companies and focuses on the field of immuno-oncology, while further broadening the Sutro platform for discovery, development,

Melanoma can be caused by abnormal changes or mutations in a cell protein called BRAF V600. The drug is recommended for people whose melanoma has spread or cannot

WCCT Global’s patient recruitment division "In-Site" is comprised of 12 key elements to ensure patient enrollment and retention. The rescue program that was effective as of October 1st

Christopher Henderson, Ph.D., joins as vice president, Neurology. Richard Ransohoff, M.D., joins as senior research fellow, Neuroimmunology. The addition of these top researchers bolsters Biogen Idec’s discovery engine.

The prospective, randomized, double-blind, placebo controlled trial was carried out in the US under a US Food and Drug Administration (FDA) Investigational New Drug (IND) protocol. The trial